Form 4: INSMED CEO Lewis Executes Pre-Planned Stock Transactions

INSMED Inc.'s Chair and CEO, William Lewis, executed pre-planned option exercises and corresponding stock sales totaling 10,699 shares on March 5, 2026, under a 10b5-1 trading plan.

Summary

• William Lewis, Chair and CEO of INSMED Inc., engaged in stock transactions on March 5, 2026.
• Transactions were executed under a Rule 10b5-1 trading plan adopted on September 4, 2025.
• Exercised options to acquire 6,259 shares of common stock at $30.46 per share.
• Exercised options to acquire 4,440 shares of common stock at $17.16 per share.
• Sold a total of 10,699 shares of common stock in multiple transactions at weighted average prices ranging from $144.23 to $147.54 per share.
• The net effect of the exercises and sales was a zero change in directly held shares from these specific transactions.
• Following these transactions, Lewis directly owns 301,185 shares and indirectly owns 233,924 shares through the Katie Procter Dynasty Trust.
• Lewis no longer reports beneficial interest in securities owned by the William Lewis Family Legacy Trust.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While a sale of shares by a CEO can sometimes be seen negatively, the execution under a 10b5-1 plan mitigates concerns about opportunistic selling, and the high sale prices reflect strong stock performance.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to recent company news.
• The sale prices for the common stock were significantly higher than the exercise prices of the options, indicating a profitable transaction for the insider.

Negatives

• The CEO sold a substantial number of shares (10,699 shares), which could be perceived negatively by some investors, even if pre-planned.
• The reporting person no longer has a reportable beneficial interest in the William Lewis Family Legacy Trust, which implies a reduction in total reported beneficial ownership.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under 10b5-1 plans, are common for executives seeking to diversify their holdings or manage liquidity without being subject to accusations of trading on material non-public information. These transactions typically do not reflect a change in the executive's view of the company's future prospects.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures for insider transactions across all publicly traded companies in the U.S.
• The execution of a 10b5-1 plan is a common practice among executives at companies like Pfizer, Merck, and Johnson & Johnson to manage their equity holdings in a compliant manner.
• The specific details of share numbers and prices are unique to INSMED and William Lewis, but the mechanism of the transaction aligns with typical corporate governance practices for insider stock sales.

Related Party Transactions

• Indirect beneficial ownership of 233,924 shares is held through the Katie Procter Dynasty Trust.
• The reporting person no longer has a reportable beneficial interest in securities owned by the William Lewis Family Legacy Trust.

Stakeholder Impact

• Shareholders may view the sale as a normal part of executive compensation and diversification, especially given the 10b5-1 plan. The high sale price could be seen as a positive indicator of stock value.
• No direct impact on employees, customers, suppliers, or creditors is indicated by this filing.

Next Steps

• Remaining stock options will continue to vest according to their schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.

Key Dates

Recommendation

The transactions represent routine insider activity under a pre-established 10b5-1 plan, indicating a planned liquidity event rather than a change in the executive's outlook on the company. While the CEO sold a significant number of shares, the sales were offset by option exercises, resulting in no net change in directly held shares from these specific transactions. The high sale prices reflect a strong stock performance. This filing does not provide new fundamental information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

INSMED Inc., INSM, William Lewis, CEO, Director, Form 4, Insider Trading, Stock Option Exercise, Stock Sale, 10b5-1 Plan, Beneficial Ownership